Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 28 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
19(67.9%)
Early Phase 1
8(28.6%)
N/A
1(3.6%)
28Total
Phase 1(19)
Early Phase 1(8)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT07406984Phase 1Not Yet Recruiting

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction

Role: lead

NCT06886919Early Phase 1Not Yet Recruiting

Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Role: lead

NCT06852573Phase 1Not Yet Recruiting

Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus

Role: lead

NCT06718738Phase 1Recruiting

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

Role: lead

NCT06690359Early Phase 1Not Yet Recruiting

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Role: lead

NCT06691308Early Phase 1Not Yet Recruiting

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

Role: lead

NCT06412458Phase 1Not Yet Recruiting

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Role: lead

NCT06209671Phase 1Unknown

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Role: lead

NCT03585517Phase 1Completed

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

Role: lead

NCT05480501Early Phase 1Unknown

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT05478343Early Phase 1Unknown

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Role: lead

NCT05309213Phase 1Unknown

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT05287165Early Phase 1Unknown

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

Role: lead

NCT05275062Early Phase 1Unknown

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Role: lead

NCT05155215Phase 1Unknown

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Role: lead

NCT05123209Phase 1Unknown

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Role: lead

NCT05117138Phase 1Unknown

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Role: lead

NCT04951141Early Phase 1Unknown

Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors

Role: lead

NCT04766840Phase 1Unknown

Donor-derived CAR-T Cells in the Treatment of AML Patients

Role: lead

NCT04336501Not ApplicableUnknown

Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Role: lead